These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 12527909

  • 1. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Hermann E, Pliquett U, Neumann E, Zeuzem S.
    Oncogene; 2003 Jan 09; 22(1):69-80. PubMed ID: 12527909
    [Abstract] [Full Text] [Related]

  • 2. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
    Spänkuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmüller M, von Minckwitz G, Kaufmann M, Strebhardt K.
    Oncogene; 2002 May 09; 21(20):3162-71. PubMed ID: 12082631
    [Abstract] [Full Text] [Related]

  • 3. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K.
    Cancer Res; 2006 Jun 01; 66(11):5836-46. PubMed ID: 16740723
    [Abstract] [Full Text] [Related]

  • 4. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R, Carbone R, Reiss M, Lacy J.
    Clin Cancer Res; 2003 May 01; 9(5):1931-9. PubMed ID: 12738752
    [Abstract] [Full Text] [Related]

  • 5. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
    Thallinger C, Wolschek MF, Maierhofer H, Skvara H, Pehamberger H, Monia BP, Jansen B, Wacheck V, Selzer E.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4185-91. PubMed ID: 15217956
    [Abstract] [Full Text] [Related]

  • 6. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD.
    Clin Cancer Res; 2000 Jul 15; 6(7):2891-902. PubMed ID: 10914739
    [Abstract] [Full Text] [Related]

  • 7. Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice.
    Uchida T, Gao JP, Wang C, Satoh T, Itoh I, Muramoto M, Hyodo T, Irie A, Akahoshi T, Jiang SX, Kameya T, Baba S.
    Mol Urol; 2001 Jul 15; 5(2):71-8. PubMed ID: 11690551
    [Abstract] [Full Text] [Related]

  • 8. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G, Scarsella M, Semple SC, Mottolese M, Natali PG, Leonetti C.
    Clin Cancer Res; 2005 Mar 01; 11(5):1990-8. PubMed ID: 15756025
    [Abstract] [Full Text] [Related]

  • 9. Polo-like kinase1, a new target for antisense tumor therapy.
    Elez R, Piiper A, Giannini CD, Brendel M, Zeuzem S.
    Biochem Biophys Res Commun; 2000 Mar 16; 269(2):352-6. PubMed ID: 10708555
    [Abstract] [Full Text] [Related]

  • 10. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
    Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A.
    Clin Cancer Res; 2002 Apr 16; 8(4):1277-83. PubMed ID: 11948143
    [Abstract] [Full Text] [Related]

  • 11. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G, Caputo R, Damiano V, Bianco R, Fontanini G, Cuccato S, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2001 Aug 16; 7(8):2537-44. PubMed ID: 11489837
    [Abstract] [Full Text] [Related]

  • 12. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
    Cho YS, Kim MK, Tan L, Srivastava R, Agrawal S, Cho-Chung YS.
    Clin Cancer Res; 2002 Feb 16; 8(2):607-14. PubMed ID: 11839683
    [Abstract] [Full Text] [Related]

  • 13. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C, Pei J, Kumar D, Sakabe I, Boudreau HE, Gokhale PC, Kasid UN.
    Methods Mol Biol; 2007 Feb 16; 361():163-85. PubMed ID: 17172711
    [Abstract] [Full Text] [Related]

  • 14. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
    Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, Calabretta B, Zupi G.
    Cancer Res; 1998 Jan 15; 58(2):283-9. PubMed ID: 9443406
    [Abstract] [Full Text] [Related]

  • 15. [Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma].
    Kim R, Emi M, Matsuura K, Tanabe K.
    Gan To Kagaku Ryoho; 2005 Oct 15; 32(11):1540-5. PubMed ID: 16315863
    [Abstract] [Full Text] [Related]

  • 16. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV, Johnson NR, Stewart T, Abrams S, Cho-Chung YS.
    Clin Cancer Res; 2005 Aug 15; 11(16):5950-5. PubMed ID: 16115938
    [Abstract] [Full Text] [Related]

  • 17. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F, Brignole C, Marimpietri D, Di Paolo D, Zancolli M, Pagnan G, Ponzoni M.
    Ann N Y Acad Sci; 2004 Dec 15; 1028():90-103. PubMed ID: 15650235
    [Abstract] [Full Text] [Related]

  • 18. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J.
    Clin Cancer Res; 1999 Oct 15; 5(10):2891-8. PubMed ID: 10537358
    [Abstract] [Full Text] [Related]

  • 19. [Effect of antisense RNA targeting Polo-like kinase 1 on cell cycle of lung cancer cell line A549].
    Zhou Q, Bai M, Su Y.
    Ai Zheng; 2005 Feb 15; 24(2):149-54. PubMed ID: 15694023
    [Abstract] [Full Text] [Related]

  • 20. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
    Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V, Hero B, Eggert A, Berthold F, Fischer M.
    Clin Cancer Res; 2011 Feb 15; 17(4):731-41. PubMed ID: 21169242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.